Commerzbank Ag set a €124.00 ($147.62) price target on Bayer AG (FRA:BAYN) in a report published on Friday morning. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other equities research analysts have also weighed in on the company. Warburg Research set a €121.00 ($144.05) price objective on Bayer AG and gave the stock a buy rating in a research note on Wednesday, September 13th. Independent Research GmbH set a €120.00 ($142.86) price objective on Bayer AG and gave the stock a neutral rating in a research note on Wednesday, September 13th. J P Morgan Chase & Co reissued a buy rating on shares of Bayer AG in a research note on Wednesday, September 13th. UBS AG set a €125.00 ($148.81) price objective on Bayer AG and gave the stock a buy rating in a research note on Wednesday, September 13th. Finally, Baader Bank set a €120.00 ($142.86) price objective on Bayer AG and gave the stock a neutral rating in a research note on Wednesday, September 13th. Nine research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Bayer AG has an average rating of Buy and an average price target of €119.55 ($142.32).

Bayer AG (FRA BAYN) opened at 110.815 on Friday. Bayer AG has a 12-month low of €85.72 and a 12-month high of €123.83. The firm has a market capitalization of €96.64 billion and a PE ratio of 19.169. The stock has a 50 day moving average price of €107.97 and a 200-day moving average price of €111.21.

ILLEGAL ACTIVITY WARNING: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/18/commerzbank-ag-reiterates-124-00-price-target-for-bayer-ag-bayn.html.

About Bayer AG

.

Analyst Recommendations for Bayer AG (FRA:BAYN)

Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.